Usually directors and high end employes are offered special incentives such as being offered new shares in the company that is taken over, or to keep their existing shares as happened in the recentt Ausenco takeover.
Further the reports that are written by so called independant companies who are supposably giving independant view point about the advantages / disadvantages of the TO are certany not going to be independant as the board has already stated that they are in favour, so the board is unlikely to hire a company with a differering view to its own to give an anaylisis.
Takeovers are generally only good for the company taking the other over and not the share holders whom are being cheated out of its real value simply because they don't realise how much its really worth.
I think share holders should vote against this take over in favour of a longer term much more profitable licencing deal perhaps with a small upfront payment and depeding on the size of the upfront payment a 10 to 20% royalty on sales.
I see that a take over is the result weak negotiating by management and a lack of management ability to relay the value of its technology to more than one potentual big Pharma company.
- Forums
- ASX - By Stock
- RHS
- Ann: PerkinElmer to acquire RHS
Ann: PerkinElmer to acquire RHS, page-8
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RHS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online